Report cover image

Advanz Pharma Corp. - Strategic SWOT Spotlight

Publisher Quaintel Research
Published Aug 27, 2024
Length 44 Pages
SKU # QTELR19119626

Description

Advanz Pharma Corp. - Strategic SWOT Spotlight


Advanz Pharma Corp. - Strategic SWOT Spotlight is a comprehensive and easily accessible overview of The Advanz Pharma Corp.'s business operations. It provides a Snapshot of the company's position in the industry compared to competitors. The report includs key executives, products and services, ESG spotlight, Corporate Strategy, Business Description, Helicopter view of SWOT Analysis, Competitive Landscape and latest events.

Key Highlights

Advanz Pharma Corp is a global pharmaceutical company headquartered at London UK. Established in 1961, Advanz Pharma Corp specializes in the development, manufacturing, and commercialization of niche and established medicines. With a focus on providing essential treatments for patients in need, the company operates in multiple segments within the pharmaceutical industry.

Advanz Pharma Corp's operations span across various geographic regions, including North America, Europe, and Asia-Pacific. Leveraging its global presence, the company is dedicated to expanding access to high-quality medicines and improving healthcare outcomes worldwide. By collaborating with healthcare professionals, regulatory authorities, and industry partners, Advanz Pharma Corp strives to address unmet medical needs and enhance patient care across diverse therapeutic areas.

With a commitment to innovation and excellence, Advanz Pharma Corp continuously seeks to advance its portfolio of pharmaceutical products. The company's diverse range of medicines encompasses both branded and generic treatments, catering to a broad spectrum of medical conditions. Through a combination of strategic partnerships, research and development initiatives, and operational excellence, Advanz Pharma Corp aims to remain at the forefront of the pharmaceutical industry, delivering value to patients, healthcare providers, and stakeholders globally.

Advanz Pharma Corp. in the News:-
  • 27-Mar-2024 - ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP (cefepime/enmetazobactam) for the treatment of severe infections
  • 26-Jan-2024 - ADVANZ PHARMA receives positive CHMP opinion for EXBLIFEP (cefepime/enmetazobactam)
  • 07-Nov-2023 - ADVANZ PHARMA acquires global rights to Androcur from Bayer
  • 18-Oct-2023 - ADVANZ PHARMA further strengthens its global portfolio of specialty brands
  • 04-Oct-2023 - ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand
Scope

Company Fundamentals:- These fundamentals offer valuable insights into Advanz Pharma Corp.'s operations, geographical presence, products and services, ESG spotlight, Corporate Strategy, Business Description and SWOT spotlight, aiding in a comprehensive understanding of the organization.

Reasons to Buy
  • Helicopter view of company's internal and external factors through SWOT analysis - Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers. - Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations. - Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Table of Contents

44 Pages
Table of Contents
Tables
Charts
Advanz Pharma Corp. - Key Company Facts
Advanz Pharma Corp. - Company Description
Advanz Pharma Corp. - Top Executives
Advanz Pharma Corp. - Head Office & Locations
Head Office - Country
Advanz Pharma Corp. - Products and Services
Products
Services
Advanz Pharma Corp. - Corporate Strategy
Advanz Pharma Corp. - Business Description
Branded Generics
Generic Pharmaceuticals
Specialty Pharmaceuticals
Advanz Pharma Corp. - ESG Spotlight
Environment
Social
Corporate Governance
Advanz Pharma Corp. - SWOT Spotlight
Overview
Strengths
Weaknesses
Opportunities
Threats
Competing Players
Snapshot of Competing Players
Perrigo Company plc
Key Company Facts
Company Description
Key Financials:
Endo Inc
Key Company Facts
Company Description
Amneal Pharmaceuticals Inc
Key Company Facts
Company Description
Key Financials:
TMC Pharma Services Ltd
Key Company Facts
Company Description
Accord Healthcare Limited
Key Company Facts
Company Description
Advanz Pharma Corp. - In the News
27-Mar-2024- ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP (cefepime/enmetazobactam) for the treatment of severe infections
26-Jan-2024- ADVANZ PHARMA receives positive CHMP opinion for EXBLIFEP (cefepime/enmetazobactam)
07-Nov-2023- ADVANZ PHARMA acquires global rights to Androcur from Bayer
18-Oct-2023- ADVANZ PHARMA further strengthens its global portfolio of specialty brands
04-Oct-2023- ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Research Methodology
Disclaimer
Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us